Literature DB >> 22218503

[Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer].

M Bremer1.   

Abstract

Entities:  

Year:  2012        PMID： 22218503     DOI： 10.1007/s00066-011-0033-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer?

Authors:  Philippe Nickers; Johanne Hermesse; Jean-Marie Deneufbourg; Sophie Vanbelle; Eric Lartigau
Journal:  Radiother Oncol       Date:  2010-08-17       Impact factor: 6.280

2.  Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.

Authors:  A A Martinez; I Pataki; G Edmundson; E Sebastian; D Brabbins; G Gustafson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-01-01       Impact factor: 7.038

3.  Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.

Authors:  Alvaro A Martinez; Jose Gonzalez; Hong Ye; Mihai Ghilezan; Sugandh Shetty; Kenneth Kernen; Gary Gustafson; Daniel Krauss; Frank Vicini; Larry Kestin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-01       Impact factor: 7.038

4.  Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.

Authors:  David J Brenner; Alvaro A Martinez; Gregory K Edmundson; Christina Mitchell; Howard D Thames; Elwood P Armour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038
  4 in total
  1 in total

1.  [Rules and regulations applying to incidents in radiotherapy].

Authors:  F Lohr; W Baus; H Vorwerk; B Schlömp; L André; D Georg; N Hodapp
Journal:  Strahlenther Onkol       Date:  2012-05-16       Impact factor: 3.621
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.